29 citations
,
December 2012 in “Fibrogenesis & Tissue Repair” This review discusses the roles of tissue-specific and mesenchymal stromal cells in tissue repair and reparative disorders, highlighting potential therapeutic targets for muscle, heart, and lung tissues.
256 citations
,
October 2013 in “Nature Communications” This study demonstrates that bioengineered lacrimal gland germs can successfully develop and restore tear production and ocular surface protection in a mouse model with lacrimal gland dysfunction.
137 citations
,
October 2009 in “The American journal of pathology” This study found that matriptase, a membrane serine protease, is crucial for maintaining multiple types of epithelial tissues in mice, with its absence leading to severe organ dysfunction and increased permeability.
86 citations
,
July 1993 in “Drugs” Finasteride treats enlarged prostate, shrinks it, improves urination, but may cause sexual dysfunction and isn't for women or children.
44 citations
,
November 2011 in “The Journal of Dermatology” This review discusses recent advancements in the management and diagnosis of primary cicatricial alopecias but reports no new clinical results; emerging insights suggest sebaceous gland dysfunction may play a role in their etiopathogenesis.
25 citations
,
January 2022 in “Endocrine journal” This study suggests that hormonal changes may contribute to the persistent symptoms of long COVID, with specific patterns observed in serum hormone levels related to fatigue and sensory dysfunction.
25 citations
,
September 2014 in “Biological Research” This study found that arctiin, a compound from Arctium lappa, demonstrated protective effects against oxidative stress-induced dysfunction in human hair dermal papilla cells, suggesting potential therapeutic use for alopecia.
24 citations
,
December 2013 in “Sexual medicine reviews” This review discusses persistent sexual and nonsexual adverse effects of the 5α-reductase inhibitor finasteride in younger men, including erectile dysfunction, low libido, and depression. It reports no new clinical results but emphasizes further research is needed.
15 citations
,
March 2020 in “Anais Brasileiros De Dermatologia” This review discusses post-finasteride syndrome, characterized by persistent symptoms despite discontinuation, and concludes that its existence cannot be confirmed; individualized assessment is advisable for those with a history of depression, sexual dysfunction, or infertility.
9 citations
,
February 2019 in “Journal of Clinical Research in Pediatric Endocrinology” In this study, children with classical congenital adrenal hyperplasia were found to have increased epicardial fat thickness, which was associated with subclinical atherosclerosis markers and left ventricular dysfunction, especially in poorly controlled cases.
1 citations
,
October 2025 in “Frontiers in Immunology” In this study, researchers analyzed adverse events linked to avacopan using FDA data, finding no high-priority safety concerns but identifying five potential new adverse events, including alopecia, primarily among American patients, and noting a higher risk of liver dysfunction in Japanese patients.
1 citations
,
May 2023 in “Farmacja Polska” This study summarizes current knowledge on the role of creatine in the human body, its applications in supplementation, and its impact on muscle mass, especially noting that animal-based foods are primary dietary sources and that women may experience health benefits from supplementation.
April 2026 in “npj Parkinson s Disease” This study found that VPS13C variants are significantly enriched in patients with idiopathic REM sleep behavior disorder (iRBD), associating these variants with more severe symptoms, autonomic dysfunction, and faster progression from iRBD to overt α-synucleinopathy in the iRBD-first disease subtype.
March 2026 in “Nature Communications” In this study, researchers conducted a large genome-wide association meta-analysis and found 30 significant genetic loci linked to the risk of dermatophytosis, shedding light on the roles of keratin biology, skin barrier defects, immune dysfunction, and obesity in the disease.
January 2025 in “Drug repurposing” This study reviewed 16 notable drug repurposing patent applications from 2025, highlighting potential new uses such as guanfacine for autonomic dysfunction and disulfiram for subarachnoid hemorrhage survival, though many disclosures lack peer-reviewed studies and no patents are granted.
April 2024 in “Canadian Women s Health Today” This review suggests that "polycystic ovarian syndrome" is a misleading name, as the disorder involves complex metabolic and reproductive issues beyond ovarian dysfunction and may stem from factors affecting the fetus in utero.
January 2024 in “International Journal of Health Science” This literature review of hormonal implants in Brazil highlights their expanding usage beyond contraceptive and hormone replacement purposes, noting aesthetic desires like muscle mass gain. However, significant side effects such as cardiovascular events and psychological complications are frequently reported, potentially outweighing the benefits.
February 1999 in “Drugs in R & D” The document concludes that various drugs for men's health issues are in development, with treatments for sexual dysfunction and prostate conditions being the most advanced.
July 2023 in “Zenodo (CERN European Organization for Nuclear Research)” In this study, the authors propose that drugs like trazodone and antipsychotics such as chlorpromazine, which can induce priapism, may help restore libido synaptic circuits, offering potential treatment for post-finasteride syndrome and post-SSRI sexual dysfunction.
January 2024 in “Wiadomości Lekarskie” This research discusses congenital torticollis, highlighting its prevalence, symptoms, and recommended treatments, which include immediate corrective exercises, physical therapy, and positioning techniques to address the muscle imbalance and prevent habitual alignment issues in affected infants.
140 citations
,
January 2021 in “Journal of the International Society of Sports Nutrition” This source reports that while creatine supplementation is popular for improving muscle mass and performance, questions about its efficacy and safety persist. An expert team is reviewing literature to address concerns like water retention, renal effects, and its benefits across different populations and uses.
July 2025 in “Scientific Reports” In this study, researchers identified six novel prognostic biomarkers for bladder cancer and developed a predictive model that effectively stratifies patients into high-risk and low-risk groups based on immune cell infiltration differences and gene expression.
March 2021 in “Research Square (Research Square)” This study found that patients with RASopathies demonstrated lower levels of serum IgA and CD8 T cells compared to controls, potentially indicating an increased risk of developing autoimmune disorders.
5 citations
,
February 2022 in “Frontiers in physiology” This review discusses the role of various cells outside the hair follicle in regulating melanocyte stem cells and hair graying, but reports no new clinical results.
7 citations
,
October 2024 in “Livers” This review highlights the connection between sex hormones and metabolic dysfunction, emphasizing how conditions like male hypogonadism and female hyperandrogenism can increase the risk and severity of hepatic steatosis, which often progresses alongside metabolic syndrome and elevates mortality risks.
2 citations
,
July 2025 in “Journal of Ovarian Research” This study found that among women with PCOS, a bedtime after midnight was independently linked to higher androgen levels and decreased lean muscle mass.
10 citations
,
January 2019 in “Archives of Endocrinology and Metabolism” This source reports that testosterone therapy may mildly improve sexual desire in women with sexual dysfunction but lacks long-term safety data and cannot be widely recommended, as no formulations are approved for women in most countries.
9 citations
,
July 2024 in “Toxins” This opinion article reviews various pathways through which onabotulinumtoxinA might work in medical treatments, highlighting applications beyond muscle paralysis, including pain inhibition and potential effects on hair loss and cancer cell apoptosis.
May 2024 in “Biochemical pharmacology” This study found that targeting CISD1 with the compound NL-1 reduced mitochondrial dysfunction and reactive oxygen species accumulation, protecting against cisplatin-induced hearing loss in cell models and mice, without affecting cisplatin's cancer-fighting effectiveness.
In this thesis, researchers explored ways to enhance the management of myotonic dystrophy type 1 by investigating the genetic inheritance patterns, especially small-sized repeat expansions, and assessing cardiac care, energy expenditure, and body composition in affected individuals.